Medical Marijuana, Inc. Major Investment AXIM Biotech Enters Clinical Study Agreement with University of British …

SAN DIEGO, Aug. 3, 2017 /PRNewswire/ — Medical Marijuana, Inc. (OTC: MJNA), the first publicly traded cannabis company in the United States, today announced that its major investment company AXIM Biotechnologies, Inc. (AXIM Biotech) (OTC: AXIM) has entered into a Clinical Study Agreement (CSA) with the University of British Columbia in Canada to begin a clinical trial with its CanChew Plus® cannabidiol (CBD) chewing gum product to treat drug-induced psychosis in adult patients.

The University will work with Health Canada and their own ethics board to design the trial, which will be conducted at the University of British Columbia, Canada, and will demonstrate the efficacy of AXIM’s chewing gum product composed of 50mg CBD to treat drug-related psychosis.

“We are proud to see AXIM Biotech embark on this new clinical trial with the University of British Columbia in Canada,” said Medical

... read more at: http://markets.businessinsider.com/news/stocks/Medical-Marijuana-Inc-Major-Investment-AXIM-Biotech-Enters-Clinical-Study-Agreement-with-University-of-British-Columbia-to-Begin-Clinical-Trial-On-CBD-Chewing-Gum-For-Treatment-of-Drug-Related-1002230628

by

Leave a Reply

Your email address will not be published. Required fields are marked *